YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer
- Conditions
- Prostate Cancer
- Registration Number
- NCT00050297
- Lead Sponsor
- Astellas Pharma Inc
- Brief Summary
The purpose of this study is to determine the optimal dosage of YM598 for slowing down disease progression in patients with rising PSA after initial therapy for localized prostate cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Not specified
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (21)
University Clinic AZ
🇧🇪Brussels, Belgium
University Clinic UCL St. Luc
🇧🇪Brussels, Belgium
Private Urology Out-patient Ward
🇨🇿Jablonec nad Nisou, Czech Republic
Clinic of Urology, University Hospital
🇨🇿Prague, Czech Republic
Hôpital Bichat, service de Urology
🇫🇷Paris, France
Haingasse 22
🇩🇪Bad Homburg, Germany
Klinik und Poliklinik für Urologie, Universitätsklinikum Carl-Gustav-Carus
🇩🇪Dresden, Germany
Klinik u. Poliklinik für Urologie, Philipps Universität, Baldingerstraße
🇩🇪Marburg, Germany
Krummbogen 15
🇩🇪Marburg, Germany
Regional Hospital, Department of Urology
🇵🇱Bydgoszcz, Poland
Scroll for more (11 remaining)University Clinic AZ🇧🇪Brussels, Belgium